Abstract
Background: Breast cancer is a cause of morbidity for more than half a million of patients in Europe, resulting in broad societal impacts that affect patients, families, and societies from a human, emotional, economic, and financial perspective. Expenditure for cancer medicines represents one of the principal driving costs of healthcare. The aim of this review is to describe the European policy and regulatory landscape of innovation uptake in breast oncology – with emphasis on value in cancer healthcare. Summary: In Europe, several reimbursement models or policy tools have been developed by countries to compose their benefit packages. The most commonly applied scheme is the product-specific eligibility model, prioritizing selected medicines and their indications. Mixed models are commonly developed, addressing the protection of more vulnerable people, ensuring protection from impoverishment caused by cancer and containing disparities. However, the risk to incur significant out-of-pocket expenses for essential or newer medicines for cancer is still substantial in Europe, especially in low- and middle-income countries, determining greater financial distress and poorer outcome for patients. Value-based priority setting is an essential mechanism to ensure timely access to the most valuable medicines for breast cancer patients. Estimations of the value of medicines can be provided within health technology assessment services and networks and informed by benefit scales and tools. Key Messages: There is ample room for reciprocal support across the diverse cultural and legal realities in Europe. The aim is common: save cancer patients from premature death by ensuring the timely access to the best care, protecting from financial hardships and distress to leave no cancer patient behind in poverty. Steps are to be taken to promote value-based priority setting, paving the way toward universal health coverage in Europe, where health of people is protected, and affordable best quality care is the only standard pursued and acceptable.
References
1.
2.
WHO
. Pricing of cancer medicines and its impacts
(2018
). Available at: https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.pdf?sequence=1&isAllowed=y (last accessed 7 July 2019).3.
OECD
. Health at a Glance: Europe 2018. STATE OF HEALTH IN THE EU CYCLE (2018
). Available at: https://ec.europa.eu/health/sites/health/files/state/docs/2018_healthatglance_rep_en.pdf (last accessed 7 July 2019).4.
Wilking
NE
, Hofmarcher
T
, Lindgren
P
, Jönsson
B
. The burden and direct cost of cancer in Europe (EU-28). J Clin Oncol [Internet]. 2016
May 20 [cited 2019 Jul 7];34(15_suppl):6618–6618. Available from: http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.66185.
Winkler
EC
, Mehlis
K
, Surmann
B
, Witte
J
, Lingnau
R
, Apostolidis
L
, et al. Financial toxicity in German cancer patients. How does a chronic disease impact the economic situation? (Abstract 1576P_PR)
. Ann Oncol
. 2018
Oct
;29
Supplement 8
:•••
. 0923-75346.
Barbaret
C
, Brosse
C
, Rhondali
W
, Ruer
M
, Monsarrat
L
, Michaud
P
, et al. Financial distress in patients with advanced cancer.
Santini D, editor. PLoS One [Internet]. 2017
May 18 [cited 2019 Jul 7];12(5):e0176470. Available from: https://dx.plos.org/10.1371/journal.pone.01764707.
Luengo-Fernandez
R
, Leal
J
, Gray
A
, Sullivan
R
. Economic burden of cancer across the European Union: a population-based cost analysis
. [Internet]
. Lancet Oncol
. 2013
Nov
;14
(12
):1165
–74
. [cited 2019 Jul 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24131614
[PubMed]
1470-20458.
Sun
L
, Legood
R
, Dos-Santos-Silva
I
, Gaiha
SM
, Sadique
Z
. Global treatment costs of breast cancer by stage: A systematic review
. [Internet]
. PLoS One
. 2018
Nov
;13
(11
):e0207993
. [cited 2019 Jul 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/30475890
[PubMed]
1932-62039.
Masaquel
C
, Jerusalem
G
, Copley-Merriman
K
, Ray
D
, Higuchi
K
, Caceres
V
. Economic Burden of Advanced Breast Cancer.
Value Heal [Internet]. 2016
May 1 [cited 2019 Jul 7];19(3):A146. Available from: https://linkinghub.elsevier.com/retrieve/pii/S109830151601638710.
Helsana (CH). Treatment Costs by Agents within Helsana.
2014
. https://www.helsana.ch/docs/breast-cancer.pdf (last Access 25 June 2019).11.
Zafar
SY
, Abernethy
AP
. Financial toxicity, Part I: a new name for a growing problem
. [Internet]
. Oncology (Williston Park)
. 2013
Feb
;27
(2
):80
–1
. [cited 2019 Jul 7] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523887/
[PubMed]
0890-909112.
Tran
G
, Zafar
SY
, Tran
G
, Zafar
SY
. Financial toxicity and implications for cancer care in the era of molecular and immune therapies
. Ann Transl Med
. 2018
May
;6
(9
):166
.
[PubMed]
2305-583913.
OECD
. (2007
). PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES IN SWITZERLAND. https://www.oecd.org/switzerland/38868953.pdf (last Access 25 June 2019).14.
Dylst
P
. Reference pricing systems in Europe: characteristics and consequences.
Generics Biosimilars Initiat J [Internet]. 2012
Aug 15 [cited 2019 Jul 7];1(3–4):127–31. Available from: http://www.gabi-journal.net/reference-pricing-systems-in-europe-characteristics-and-consequences.html15.
Bouvy
JC
, Sapede
C
, Garner
S
. Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
. [Internet]
. Front Pharmacol
. 2018
Mar
;9
:280
. [cited 2019 Jul 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/29636692
[PubMed]
1663-981216.
WHO EURO
. Medicines reimbursement policies in Europe
(2018
). Available at: http://www.euro.who.int/__data/assets/pdf_file/0011/376625/pharmaceutical-reimbursement-eng.pdf?ua=1 (last Access: 26 June 2019).17.
Kawalec
P
, Stawowczyk
E
, Tesar
T
, Skoupa
J
, Turcu-Stiolica
A
, Dimitrova
M
, et al. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
. [Internet]
. Front Pharmacol
. 2017
Jun
;8
:288
. [cited 2019 Jul 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28642700
[PubMed]
1663-981218.
Moorkens
E
, Vulto
AG
, Huys
I
, Dylst
P
, Godman
B
, Keuerleber
S
, et al. Policies for biosimilar uptake in Europe: an overview
. [Internet]
. PLoS One
. 2017
Dec
;12
(12
):e0190147
. [cited 2019 Jul 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/29284064
[PubMed]
1932-620319.
Tabernero
J
, Vyas
M
, Giuliani
R
, Arnold
D
, Cardoso
F
, Casali
PG
, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
. [Internet]
. ESMO Open
. 2017
Jan
;1
(6
):e000142
. [cited 2019 Jul 7] Available from: http://esmoopen.bmj.com/lookup/doi/10.1136/esmoopen-2016-000142
[PubMed]
2059-702920.
Cherny
N
, Sullivan
R
, Torode
J
, Saar
M
, Eniu
A
, Cherny
N
, et al. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
. Ann Oncol
. 2016
Aug
;27
(8
):1423
–43
.
[PubMed]
0923-753421.
WHO
. WHO Model List of Essential Medicines
(2017
). Available at: https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf (last access 7 July 2019).22.
Curigliano
G
, Burstein
HJ
, Winer
EP
, Gnant
M
, Dubsky
P
, Loibl
S
, et al.; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
. Ann Oncol
. 2017
Aug
;28
(8
):1700
–12
.
[PubMed]
0923-753423.
Cherny
NI
, Dafni
U
, Bogaerts
J
, Latino
NJ
, Pentheroudakis
G
, Douillard
JY
, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1
. [Internet]
. Ann Oncol
. 2017
Oct
;28
(10
):2340
–66
. [cited 2018 Aug 26] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28945867
[PubMed]
0923-753424.
OECD
. Cancer Care: Assuring quality to improve survival (2013). Available at: http://www.oecd.org/ (last Access: 26 June 2019
).25.
Choi
E
, Lee
S
, Nhung
BC
, Suh
M
, Park
B
, Jun
JK
, et al. Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries
. [Internet]
. Epidemiol Health
. 2017
Feb
;39
:e2017006
. Available from: http://www.e-epih.org/journal/view.php?doi=10.4178/epih.e2017006
[PubMed]
2092-719326.
Ellis
L
, Belot
A
, Rachet
B
, Coleman
MP
. The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival
. [Internet]
. J Glob Oncol
. 2019
May
;5
(5
):1
–9
. [cited 2019 Jul 7] Available from: https://ascopubs.org/doi/10.1200/JGO.19.00038
[PubMed]
2378-950627.
Vrdoljak
E
, Bodoky
G
, Jassem
J
, Popescu
R
, Pirker
R
, Čufer
T
, et al. Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe
. Oncologist
. 2019
Jan
;24
(1
):e30
–7
.
[PubMed]
1083-715928.
European Parliament
. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare (2011
). Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32029.
WHO
. Health technology assessment (2019
). Available at: https://www.who.int/medical_devices/assessment/en/ (last access 7 July 2019).30.
WHO
. SIXTY-SEVENTH WORLD HEALTH ASSEMBLY. WHA67 Resolutions (2014). Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA67-REC1/A67_2014_REC1-en.pdf (last access 7 July 2019). EMA. Health technology assessment bodies (2019
). Available at: https://www.ema.europa.eu/en/partners-networks/health-technology-assessment-bodies (Last access 7 July 2019). EUnetHTA. Available at: https://www.eunethta.eu/ (last access 7 July 2019).31.
EMA. Health technology assessment bodies (2019). Available from: https://www.ema.europa.eu/en/partners-networks/health-technology-assessment-bodies (Last access 7 July 2019).
32.
EUnetHTA. Available from: https://www.eunethta.eu/ (last access 7 July 2019).
33.
Reuzel
RP
, van der Wilt
GJ
, ten Have
HA
, de Vries Robbé
PF
. Reducing normative bias in health technology assessment: Interactive evaluation and casuistry. Med Heal Care Philos [Internet]. 1999
[cited 2019 Jul 7];2(3):255–63. Available from: http://link.springer.com/10.1023/A:100996301881334.
Hammerman
A
, Greenberg-Dotan
S
, Feldhamer
I
, Birnbaum
Y
, Cherny
NI
. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel
. [Internet]
. Expert Rev Pharmacoecon Outcomes Res
. 2018
Feb
;18
(1
):119
–22
. [cited 2019 Jul 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28617621
[PubMed]
1473-716735.
Wild
C
, Grössmann
N
, Bonanno
PV
, Bucsics
A
, Furst
J
, Garuoliene
K
, et al. Utilisation of the ESMO-MCBS in practice of HTA
. [Internet]
. Ann Oncol
. 2016
Nov
;27
(11
):2134
–6
. [cited 2019 Jul 7] Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdw297
[PubMed]
0923-753436.
Institute for Health Informatics
. Delivering on the potential of biosimilar medicines.
Parsippany: IMS Institute for Health Informatics (2016
). Available at: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-Mar© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
